Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Blueprint Medicines

Stocks Showing Improving Market Leadership: Blueprint Medicines Earns 81 RS Rating

A Relative Strength Rating upgrade for Blueprint Medicines shows improving technical performance.

Investors Business Daily

Stocks Showing Improved Relative Strength: Blueprint Medicines

Blueprint Medicines shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

How IBD Stock Of The Day Blueprint Medicines 'Knocked It Out Of The Park'

Blueprint Medicines is Tuesday's IBD Stock Of The Day. Shares are breaking a trendline, giving investors an early entry within a flat base.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Blueprint Medicines Surges After Rare-Disease Drug Notches Its Fourth Quarterly Beat

Revenue from highly rated Blueprint Medicine's rare-disease drug topped fourth-quarter expectations, and BPMC stock surged.

Investors Business Daily

Chart of the Day: Does Blueprint Medicines Have a Blueprint for Success?

The Chart of the Day belongs to the cancer biomedical company Blueprint Medicines (BPMC) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the...

Barchart

Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022

Upgrades

Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint

Blueprint unveiled the "long-awaited" results of its study in indolent systemic mastocytosis on Wednesday, and the biotech stock crashed.

Investors Business Daily

This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation'

Today Blueprint Medicines Corp (NASDAQ:BPMC) announced strategic financing agreements with Sixth Street and Royalty Pharma Plc (NASDAQ:RPRX) for up to $1.25 billion, including $575 million upfront upon deal closure. SVB Securities thinks the terms of the deals are fairly valued on the Sixth Street portion and favorable for Blueprint Medicines on the Royalty Pharma portion. "In addition,…

Benzinga

What 7 Analyst Ratings Have To Say About Blueprint Medicines

Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings:

Benzinga

SVB Leerink Maintains Market Perform Rating for Blueprint Medicines: Here's What You Need To Know

SVB Leerink has decided to maintain its Market Perform rating of Blueprint Medicines (NASDAQ:BPMC) and lower its price target from $82.00 to $60.00. Shares of Blueprint Medicines are trading down 8.32% over the last 24 hours, at $44.07 per share.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022

Benzinga

4 Analysts Have This to Say About Blueprint Medicines

Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:

Benzinga

Blueprint Stock Dives On The FDA's Tricky New Requirement For Its Leading Drug

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022

Upgrades

Benzinga

What 3 Analyst Ratings Have To Say About Blueprint Medicines

Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:

Benzinga

Blueprint Medicines: Q1 Earnings Insights

Blueprint Medicines (NASDAQ:BPMC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Earnings Preview: Blueprint Medicines

Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Blueprint Medicines will report an earnings per share (EPS) of $-1.94.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Blueprint Medicines Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET

Blueprint Medicines (NASDAQ:BPMC) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.

Benzinga

Where Blueprint Medicines Stands With Analysts

Over the past 3 months, 6 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

What 5 Analyst Ratings Have To Say About Blueprint Medicines

Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Blueprint Medicines, Proteovant Collaboration For Protein Degrader Therapies

Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics have entered a

Benzinga

Where Blueprint Medicines Stands With Analysts

Benzinga

Earnings Preview: Blueprint Medicines

Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that Blueprint Medicines will report an earnings per share (EPS) of $-1.65.

Benzinga

EMA's Advisory Committee Recommends Approval Of Blueprint Medicines' Avapritinib In Blood Disorder

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has

1 2

People

Andrew Berens

19 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.